MX2025014082A - Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2) - Google Patents

Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2)

Info

Publication number
MX2025014082A
MX2025014082A MX2025014082A MX2025014082A MX2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A MX 2025014082 A MX2025014082 A MX 2025014082A
Authority
MX
Mexico
Prior art keywords
crystal
compound
nitrogen
activation effect
heterocyclic compound
Prior art date
Application number
MX2025014082A
Other languages
English (en)
Spanish (es)
Inventor
Tomoya Iwata
Noriyuki Takata
Masato Kono
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2025014082A publication Critical patent/MX2025014082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2025014082A 2023-06-19 2025-11-25 Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2) MX2025014082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (1)

Publication Number Publication Date
MX2025014082A true MX2025014082A (es) 2026-01-07

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025014082A MX2025014082A (es) 2023-06-19 2025-11-25 Cristal de compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del factor 2 relacionado con el factor nuclear eritroide 2 (nrf2)

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
GB202005852D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
CR20240325A (es) 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
JP7904995B2 (ja) 2026-08-13
IL324833A (en) 2026-01-01
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
CN121152792A (zh) 2025-12-16
WO2024262491A1 (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
CR20220251A (es) Nuevos derivados de metilquinazolinona
SG11201804121RA (en) Novel biphenyl compound or salt thereof
SA521422143B1 (ar) 15-pgdh مثبط
EA202192138A1 (ru) Гетероциклическое соединение и его применение
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
MX391414B (es) Compuesto novedoso de bifenilo o sal del mismo.
AU2018312326A2 (en) Heterocyclic compound and use thereof
MX2019010261A (es) Derivados de oxadiazol microbicidas.
EP4474017A3 (en) New heterocyclic compounds
BR112022001191A2 (pt) Combinações fungicidas, misturas e composições e usos das mesmas
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MX2022008665A (es) Nuevo derivado de pirazol.
WO2021053402A3 (en) Sulfonamide derivatives as ctps1 inhibitors
PH12018502513A1 (en) Sulfonamide compound or salt thereof
MX2021004474A (es) Compuestos que contienen deuterio.
MX2020005077A (es) Compuestos con acción estabilizadora, procedimiento para su preparación, composición que contiene estos compuestos estabilizadores, procedimiento para la estabilización de un componente orgánico así como uso de compuestos estabilizadores.
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
MX2021003427A (es) Nuevos oxadiazoles.
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
EA202192134A1 (ru) Амидзамещенные гетероциклические соединения
MX2020012760A (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
MX2020001615A (es) Compuestos de piridina sustituidos con azol.
MX2019014406A (es) Compuesto heterociclico y composicion que contiene el mismo.